291 results on '"Sällberg M"'
Search Results
2. A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells
3. Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure
4. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine
5. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene
6. 27P Methodology for identification of clinically relevant targets for TCR-immunotherapy in hepatocellular carcinoma
7. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo
8. Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy
9. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes
10. The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor α mediated liver disease
11. Relation between viral fitness and immune escape within the hepatitis C virus protease
12. Synthetic peptides as mini antibodies
13. Site-directed serology of HIV-1 subtype B infection: relation between virus specific antibody levels and disease progression
14. Full analysis of comorbidities in chronic hepatitis Cpatients compared with matched comparators: A nationwide population-based register study from 2001 to 2013
15. Lower risk of multiple sclerosis in patients with chronic hepatitis C: A nationwide population-based register study 2001-2013
16. Chronic hepatitis C diagnosis increases sick leave and disability pension
17. Depletion of CD4+CD25+ regulatory T cells attenuates the development of CCl4-induced liver fibrosis in HCV nonstructural protein 3/4A transgenic mice
18. Long-term follow-up of successful hepatitis C virus therapy : waning immune responses and disappearance of liver disease are consistent with cure.
19. THU-395 - Lower risk of multiple sclerosis in patients with chronic hepatitis C: A nationwide population-based register study 2001-2013
20. THU-394 - Full analysis of comorbidities in chronic hepatitis Cpatients compared with matched comparators: A nationwide population-based register study from 2001 to 2013
21. P763 ANALYSIS OF HCV MARKERS AND IMMUNE RESPONSES 5–20 YEARS AFTER SUCCESSFUL HCV THERAPY SUGGESTS THAT MOST PATIENTS ARE CURED
22. P183 A THERAPEUTIC VACCINE BASED ON THE HEPATITIS B CORE ANTIGEN IN COMBINATION WITH INTERLEUKIN-12 EFFECTIVELY INDUCES IMMUNE RESPONSES IN HBV-TRANSGENIC MICE
23. P202 EVALUATION OF A HEPATITIS C VIRUS THERAPEUTIC VACCINE CANDIDATE IN WILDTYPE- AND HCV-TRANSGENIC MICE
24. 320 THE HEPATITIS C VIRUS NON-STRUCTURAL 3/4A PROTEASE MEDIATES AN INTRAHEPATIC T HELPER(Th)-1 TO Th2 SHIFT BY CLEAVING THE T CELL PROTEIN TYROSINE PHOSPHATASE
25. Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tickIxodes ricinus; possible relationship with red meat allergy
26. 770 THE HCV NS3/4A-MEDIATED IMPAIRMENT OF THE HEPATIC ANTIVIRAL IMMUNE RESPONSE IS REVERSED BY PROTEASE INHIBITION OR RIBAVIRIN IN VIVO
27. 761 IN VIVO INTRACELLULAR INJECTION NEEDLE (IVIN) TECHNOLOGY: A NEW NEEDLE FOR IMPROVED CELLULAR UPTAKE OF DNA IN A LIVE ANIMAL
28. 1207 HETEROLOGOUS T CELLS CAN HELP RESTORE FUNCTION IN DYSFUNCTIONAL HEPATITIS C VIRUS SPECIFIC T CELLS DURING THERAPEUTIC VACCINATION
29. Perspectives on hepatitis B infections and the efficacy of vaccination (hepatitis B and pneumococci) in dialysis patients
30. 680 HCV NS3/4A INTERFERES WITH INTRAHEPATIC IMMUNITY AND TNFA-INDUCED LIVER DAMAGE BY MODULATING CCL17 AND CXCL9 SECRETION IN VIVO
31. 681 HCV NS3/4A-MEDIATED CCL2 AND TNFA SECRETION INCREASE HEPATOCYTE SURVIVAL AND LIVER REGENERATION IN VIVO
32. 608 IMPROVING ON THE ABILITY OF ENDOGENOUS HEPATITIS B CORE ANTIGEN TO PRIME CYTOTOXIC T LYMPHOCYTES
33. 116 COMBINATION THERAPY WITH THERAPEUTIC VACCINATION AND INHIBITION OF PD-L1 IMPROVES T CELL FUNCTION IN HCV-TRANSGENIC MICE
34. 318 THE HEPATITIS C VIRUS ENHANCES ACTIVATION OF THE EGF-RECEPTOR AND AKT-ACTIVITY BY NS3/4A-MEDIATED CLEAVAGE OF THE T-CELL PROTEIN TYROSINE PHOSPHATASE
35. The hepatitis C virus non-structural 3/4A protease activates Akt-dependent host cell signaling which is required for sufficient viral replication
36. Herpesvirus serology, aberrant specific immunoglobulin G2 and G3 subclass patterns and Gm allotypes in individuals with low levels of IgG3
37. Modifikation TNF-alpha induzierter Signalvermittlung durch das NS3/4A-Protein des Hepatitis C Virus in NS3/4A transgenen Mäusen
38. Perspectives on Hepatitis B Infections and the Efficacy of Vaccination (Hepatitis B and Pneumococci) in Dialysis Patients
39. Modeling the T-helper cell response in acute and chronic hepatitis B virus infection using T-cell receptor transgenic mice
40. Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4 + T-Cell Repertoire in Chronic Hepatitis B Virus Infection
41. Nanospray mass spectrometry for identification of peptides. Application of a novel interface.
42. Metabolic fate of nociceptin/orphanin FQ in the rat spinal cord and biological activity of its released fragment
43. Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products
44. Subtyping of human immunodeficiency virus type 1 strains by using antibodies specific for the third variable domain (V3) of gp120: results may be affected by divergent V3 sequences
45. Differences in humoral responses to the p24 antigen between Ethiopian and Swedish human immunodeficiency virus type 1-infected patients may suggest influences from a T-helper 2-like phenotype
46. Antibodies to the hepatitis B e antigen (HBeAg) can be induced in HBeAg-transgenic mice by adoptive transfer of a specific T-helper 2 cell clone
47. Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens
48. Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens
49. Detection of hepatitis G virus (GB virus C) RNA in human saliva
50. The Honduran human immunodeficiency virus type 1 (HIV-1) epidemic is dominated by HIV-1 subtype B as determined by V3 domain sero- and genotyping
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.